Alan F. List

Sort by:

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Pierre Fenaux, Ghulam J. Mufti, +16 authors Lewis R. Silverman
The Lancet. Oncology
2009

BACKGROUND Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival… (More)

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Alan F. List, Gordon Dewald, +13 authors Robert D Knight
The New England journal of medicine
2006

BACKGROUND Severe, often refractory anemia is characteristic of the myelodysplastic syndrome associated with chromosome 5q31 deletion. We investigated whether lenalidomide (CC5013) could reduce the… (More)

Efficacy of lenalidomide in myelodysplastic syndromes.

Alan F. List, Sandy Kurtin, +7 authors Jerome B. Zeldis
The New England journal of medicine
2005

BACKGROUND Ineffective erythropoiesis is the hallmark of myelodysplastic syndromes. Management of the anemia caused by ineffective erythropoiesis is difficult. In patients with myelodysplastic… (More)

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q

Azra Raza, James A. Reeves, +16 authors Alan F. List
Blood
2008

Lenalidomide is approved for red blood cell (RBC) transfusion-dependent anemia due to low or intermediate-1 (int-1) risk myelodysplastic syndromes (MDSs) associated with a chromosome 5q deletion with… (More)

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Pierre Fenaux, Ghulam J. Mufti, +13 authors Lewis R. Silverman
Journal of clinical oncology : official journal…
2010

PURPOSE In a phase III randomized trial, azacitidine significantly prolonged overall survival (OS) compared with conventional care regimens (CCRs) in patients with intermediate-2- and high-risk… (More)

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.

Alan F. List, Kenneth J. Kopecky, +9 authors F R Appelbaum
Blood
2001

Cyclosporine A (CsA) inhibits P-glycoprotein (Pgp)-mediated cellular export of anthracyclines at clinically achievable concentrations. This randomized controlled trial was performed to test the… (More)

STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia.

Andrés Jerez, Michael J. Clemente, +19 authors Jaroslaw Maciejewski
Blood
2012

Chronic lymphoproliferative disorders of natural killer cells (CLPD-NKs) and T-cell large granular lymphocytic leukemias (T-LGLs) are clonal lymphoproliferations arising from either natural killer… (More)

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

Dana E. M. Rollison, Nadia Howlader, +5 authors Alan F. List
Blood
2008

Reporting of myelodysplastic syndromes (MDSs) and chronic myeloproliferative disorders (CMDs) to population-based cancer registries in the United States was initiated in 2001. In this first analysis… (More)

Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations.

Britta Will, Li Zhou, +22 authors Amit Verma
Blood
2012

Even though hematopoietic stem cell (HSC) dysfunction is presumed in myelodysplastic syndrome (MDS), the exact nature of quantitative and qualitative alterations is unknown. We conducted a study of… (More)

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.

Mikkael A. Sekeres, Alan F. List, +8 authors Jaroslaw Maciejewski
Journal of clinical oncology : official journal…
2010

PURPOSE Lenalidomide and azacitidine are active in patients with lower- and higher-risk myelodysplastic syndromes (MDS). These agents may complement each other by targeting both the bone marrow… (More)

Filter Results:

Publication Year

Publication Type

Co-author

Journals and Conferences